The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1507
Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Eteplirsen (Exondys 51 – Sarepta), an antisense oligonucleotide, has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation of the dystrophin gene that is amenable to exon 51 skipping. It is the first drug to be approved for treatment of DMD.

THE DISORDER — DMD is a progressive, X-linked, recessive, neuromuscular disorder characterized by a near-complete absence of the protein dystrophin in muscle cells. Dystrophin is essential for maintenance of myocyte integrity.1 About 1 in 3600 infant males has DMD. Patients with DMD begin experiencing progressive muscle weakness and deterioration when they are 3-5 years old and usually become nonambulatory by their early teenage years. Death almost always occurs before age 40. High-dose prednisone therapy (0.75 mg/kg/day) is commonly used to slow ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy
Article code: 1507c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian